Notes on Engineering Health, October 2022

Some Digitalis Ventures News

“Here’s a bumper sticker I’d like to see: We are the proud parents of a child who’s self-esteem is sufficient that he doesn’t need us promoting his minor scholastic achievements on the back of our car.”
–George Carlin
“I’ve said it before, and by gosh, I’ll say it again — don’t be afraid to toot your own horn.” 
–Emlyn Chand

While we would like to follow George Carlin and ignore Emlyn Chand, we’d be remiss not to feature in this month’s newsletter a recent positive development at the firm. Specifically, last week we announced the closing of our fourth fund, totaling $300 million in commitments. The new capital will be invested in leading entrepreneurs and researchers developing breakthrough science and technology with the potential to transform patients' lives.

“With this fund, we will continue to support founders looking to solve some of the hardest challenges in healthcare, providing guidance for the growth and success not only of the company but also of its leadership team," said Geoffrey W. Smith, our Founder and Managing Partner. “We're investing in solutions inspired by an engineering mindset and informed by deep technical, financial, and domain expertise. By envisioning what's possible and determining the most efficient path forward, our team will enable companies to move from technology development to clinical and market translation addressing unmet patient needs.”

Since our inception in 2016, Digitalis has invested in over 50 companies across the US, UK, and Europe. Representative investments include Good Therapeutics, whose lead conditionally active cytokine program was acquired earlier this year by Roche; GRO Biosciences, which is scaling the production of proteins that incorporate non-standard amino acids; Terray Therapeutics, which is developing an AI-powered small molecule discovery platform; Cayaba Care, which is providing home-based pregnancy care in communities that need it most; and findhelp, the leading technology provider of social care infrastructure in the US.

To advance our mission of creating a healthier world through the life sciences and healthcare technology, we've built a multidisciplinary team of investors, combined with an expansive, long-term network of entrepreneurs, academic institutions, and co-investors. Our continued aim will be for our portfolio companies to benefit from team members' accessible expertise, their deep technical understanding, and their experience in building successful businesses. Onward.

– The Digitalis Team